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Abstract Primary chronic kidney disease is associated
with high cardiovascular risk. However, the exact mecha-
nismsbehindthiscardiorenalinteractionremainunclear.We
investigated the interaction between heart and kidneys in
novel animal model for cardiorenal interaction. Normal
Wistar rats and Munich Wistar Fromter rats, spontaneously
developing renal dysfunction, were subjected to experi-
mental myocardial infarction to induce cardiac dysfunction
(CD) and combined cardiorenal dysfunction (CRD),
respectively (N = 5–10). Twelve weeks later, cardiac- and
renal parameters were evaluated. Cardiac, but not renal
dysfunction was exaggerated in CRD. Accelerated cardiac
dysfunction in CRD was indicated by decreased cardiac
output (CD 109 ± 10 vs. CRD 79 ± 8 ml/min), diastolic
dysfunction (E/e0) (CD 26 ± 2 vs. CRD 50 ± 5) and left
ventricular overload (LVEDP CD 10.8 ± 2.8 vs. CRD
21.6 ± 1.7 mmHg). Congestion in CRD was conﬁrmed by
increased lung and atrial weights, as well as exaggerated
right ventricular hypertrophy. Absence of accelerated renal
dysfunction, measured by increased proteinuria, was sup-
ported by absence of additional focal glomerulosclerosis or
further decline of renal blood ﬂow in CRD. Only advanced
peripheral endothelial dysfunction, as found in CRD,
appearedtocorrelatewithbothrenalandcardiacdysfunction
parameters. Thus, proteinuric rats with myocardial infarc-
tion showed accelerated cardiac but not renal dysfunction.
As parameters mimic the cardiorenal syndrome, these rats
may provide a clinically relevant model to study increased
cardiovascular risk due to renal dysfunction. Peripheral
endothelial dysfunction was the only parameter that corre-
lated with both renal and cardiac dysfunction, which may
indicate a mediating role in cardiorenal interaction.
Keywords Cardiorenal   Congestive heart failure  
Endothelial dysfunction
Introduction
Even mild renal dysfunction substantially increases cardio-
vascular risk [12, 20, 28]. Moreover, many patients with
heartfailuresufferfromconcomitantrenaldysfunction[19],
indicating a strong cardiorenal interaction. Although well
recognized,thepathophysiologyofthisinteractionislargely
unclear. Patients characterized by a condition of primary
chronic kidney disease [36] are at an extremely high car-
diovascular risk; 10–20-fold increased risk of cardiac death;
the 2 year mortality rate after myocardial infarction is
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generalpopulationof25%[17].Theseﬁndingshaverevived
interest in the interrelation between heart and kidneys.
To investigate the interaction between heart and kidneys
in this high-risk group of patients, different animal models
have been used so far [41]. Most studies include rats with
either unilateral [48] or 5/6 nephrectomy [9, 55] to induce (a
predisposition for) renal dysfunction, that were subjected to
chronic experimental heart failure. Although studies have
presented accelerated renal dysfunction [48], in neither
study accelerated cardiac dysfunction has been observed.
Only one study reported worsening of cardiac dysfunction
and exaggerated cardiac remodeling, but this could well be
attributed to the larger infarcts in the cardiorenal group [10].
As all models have their advantages and disadvantages, the
acute character of the nephrectomy in the above models and
the little amount of renal tissue left for therapeutic inter-
vention, provides a clear disadvantage in the translation of
the results to the human cardiorenal syndrome. We aimed to
study cardiorenal interaction in an alternative animal
model, better mimicking the clinically high-risk condition;
rats that spontaneously develop slowly progressive renal
dysfunction, subjected to experimental heart failure.
Parameters of renal as well as cardiac dysfunction were
recorded and correlated to study interaction between heart
and kidneys. As heart and kidneys are connected by vas-
culature, and endothelial function is reported to predict
outcome in cardiac as well as renal dysfunction, vascular
endothelial dysfunction was studied as potential mechanism
underlying cardiorenal interaction.
Methods
Animals
The study was performed in male Munich Wistar Fromter
rats (MWF/ZtmHsd) and age-matched Wistar rats
(HsdCpb:WU), as their genetic background (Harlan, The
Netherlands/USA). Animals were housed in groups under
standard conditions at 12 h light/dark cycle at the animal
facilities of the University of Groningen. All animals were
fed standard diet (standard rat chow, Hope Farms, Woer-
den, The Netherlands) and received food and water
ad libitum. All experiments were conducted in accordance
with the NIK Guide for the Care and Use of Laboratory
Animals and were approved by the Committee for Animal
Experiments of the University of Groningen.
Experimental protocol
At 12 weeks of age, all rats were placed in metabolic
cages for measurements of water and food intake and
24 hour urine collection. Subsequently, under 2.5% iso-
ﬂurane anaesthesia blood samples (±1.5 ml) were with-
drawn from the tail vein. Urine and plasma samples were
processed and stored at -80C for later analyses. Sub-
groups of Wistar and MWF rats (n = 5 each) were sac-
riﬁced prematurely to obtain baseline measurements of
cardiac function and to collect cardiac and renal tissue for
further analysis. The remaining animals were allowed
1 week recovery before they were subjected to permanent
coronary artery occlusion or sham surgery as described
before [52]. Five rats of each group (ECHO apparatus
became available half way through the study) underwent
echocardiography at baseline and at 3, 7 and 10–11 weeks
after surgery to evaluate the time course of cardiac
function. At the same time points, plasma and urine were
collected from all rats (metabolic cages) to examine the
time course of renal (dys)function.
Twelve weeks after surgery, measurements of left
ventricular function and cardiac and renal hemodynamics
were obtained invasively. This time point was chosen
because of anticipated endothelial dysfunction in CD
animals [13]. Blood samples were collected from the tail
vein and processed for further analyses. The heart was
dissected, weighted and cooled in ice-cold saline for
diastolic arrest. A mid-ventricular slice was processed for
histological analysis. The remaining tissue was separated
in right ventricle, interventricular septum, viable- and
infarcted left ventricle, frozen in liquid nitrogen and
stored at -80C.
Lung tissue was weighted. Kidneys were dissected,
weighted and processed for histological analysis. The
thoracic aorta was dissected and cut in rings for in vitro
endothelial function analysis [44], as well as structural
analysis.
Echocardiography
Echocardiographical measurements were obtained with the
use of a Vivid 7 (GE Healthcare) equipped with a 10 MHz
transducer. Under isoﬂurane anaesthesia (2.5%), rats were
placed on a heating pad to keep body temperature at 37C.
Images in parasternal long-axis, short-axis and four-
chamber apical view were obtained. The ejection fraction
(EF) was calculated using the Teichholz method and car-
diac output (CO) was estimated from the aortic ﬂow proﬁle
and the diameter at valvular levels as follows: CO = aortic
valve area times aortic velocity time integral times heart
rate, as described before [45]. Mitral inﬂow measurement
of early ﬁlling velocity (E) was obtained from an apical
four-chamber view using pulsed Doppler with the sample
placed at the tips of mitral leaﬂets. Tissue Doppler imaging
measurement of mitral valve septal annular velocity (e0)
was also obtained from the four-chamber apical view. All
Page 2 of 15 Basic Res Cardiol (2012) 107:242
123calculated parameters have been presented as the mean of
ﬁve consecutive beats to avoid beat-to-beat variation. As
echocardiography could have been obtained only in sub-
groups, results should be regarded as indication, rather than
as group evaluation with statistical analysis.
Blood and urine measurements
After urine collection, blood samples were obtained under
isoﬂurane anaesthesia. Measurements of plasma creatinine,
electrolytes, haemoglobin, and haematocrit levels were
performed with an iSTAT handheld analyser (ABBOTT)
and appropriate cartridges (Creatinine; EG7?). Standard
blood count was performed in whole blood samples. For
that, whole blood sampled from the tail vein was trans-
ported immediately to the hospital. Remaining blood was
processed and plasma was stored at -80C for later
analyses.
PRA was determined by Gammacoat RIA kit (Diasorin,
Minnesota, USA) according to the manufacturer’s
instructions and expressed as ngAngI/ml/h.
BNP was measured with the use of BNP-45 EIA kit
(Phoenix Pharmaceuticals, Inc).
Total urinary protein levels were determined using TCA
precipitation measurement (Nephelometer analyzer II,
Dade Behring, Marburg, Germany).
All measurements were performed according to the
manufacturer’s instructions.
Hemodynamics and cardiac function
Under isoﬂurane anaesthesia, hemodynamics and cardiac
performance were measured using a pressure transducer
catheter (Micro-Tip 3French, Millar Instruments Inc.,
Houston, TX) inserted through the right carotid artery. The
catheter was positioned in the aortic root and mean arterial
blood pressure (MAP) and heart rate (HR) were measured.
The catheter was advanced into the left ventricle, and left
ventricular systolic pressure (LVSP) and left ventricular
end-diastolic pressure (LVEDP) were recorded. The max-
imal rates of increase and decrease in left ventricular
pressure (?dP/dtmax and -dP/dtmax) were determined as
parameters of myocardial contractility and relaxation,
respectively. Then, the catheter was withdrawn and
immediately positioned in the vena cava superior just
above the heart, and central venous pressure (CVP) was
measured and total peripheral resistance (TPR) was cal-
culated as TPR = MAP - CVP/CO.
The abdominal cavity was opened and a ﬂow probe
(Transonic, Ithaca, NY, USA) was positioned on the left
renal artery [56]. After stabilization, renal blood ﬂow
(RBF) was measured. Renal vascular resistance (RVR) was
calculated as RVR = MAP - CVP/RBF.
Histology
A 1.5 mm thick mid-ventricular slice was ﬁxated in 2%
phosphate buffered paraformaldehyde for at least 24 h,
dehydrated, and embedded in parafﬁn for measurement of
infarct size and morphometric analysis of cardiac structure.
Deparafﬁnized 5 lm sections were either stained with
Sirius Red and fast green to distinguish infarct from viable
tissue and to visualize interstitial collagen; with Gomori’s
silver staining in order to visualize individual myocytes; or
with Lectin GSI to visualize capillaries. Methods as well as
the measurements of infarct size, myocyte size, capillary
density and interstitial ﬁbrosis are described in detail by
van Kerckhoven et al. [49]. Infarct size was expressed as
percentage of left ventricular circumference.
Kidneys were stained with PASS staining and scored on
presence and degree of focal glomerular sclerosis as
described before [44].
Aortic sections were stained with Virhoff staining.
Aortic hypertrophy was obtained from medial thickness,
corrected for lumen diameter, as described before [8].
Cardiomyocyte function
Force measurements were performed in single, mechani-
cally isolated cardiomyocytes as described previously [27,
50]. Brieﬂy, tissue samples were defrosted in relaxing
solution, mechanically disrupted and incubated in relaxing
solution supplemented with 0.5% Triton X-100 to remove
all membrane structures. Single cardiomyocytes were
attached with silicone adhesive between a force transducer
and a motor. Sarcomere length of isolated cardiomyocytes
was adjusted to 2.2 lm. Isometric force was measured in
maximally activating calcium solution (pCa =- 10-
log[Ca
2?] = 4.5) and in relaxation solution (pCa 9.0) to
determine maximal force generating capacity (Fmax) and
passive force (Fpas), and normalized for cardiomyocyte
cross-sectional area. On transfer of the cardiomyocyte from
relaxing to activating solution, isometric force started to
develop. Once a steady state force level was reached, the
cell was shortened within 1 ms to 80% of its original length
to determine the baseline of the force transducer. The
distance between the baseline and the steady force level is
the total force (Ftotal). The cell was re-stretched and
returned to the relaxing solution, in which a second slack
test, of 10 s duration was performed to determine passive
force. Maximal force was obtained by subtracting passive
force from the total force, i.e. Fmax = Ftotal - Fpas.
Endothelial function
Maximal endothelium-dependent relaxation was measured
in vitro in aortic rings obtained from subgroups of the
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123experimental groups, as described before [44]. Brieﬂy,
thoracic aorta segments (approximately 2 mm) were
cleaned of adherent tissue and mounted in an organ bath
with Krebs solution (pH 7.5) containing (in mmol/L): NaCl
(120.4), KCl (5.9), CaCl2 (2.5), MgCl2 (1.2), NaH2PO4
(1.2), glucose (11.5), NaHCO3 (25.0) which was kept at
37C and continuously bubbled with 95% O2 and 5% CO2.
After equilibration, viability of smooth muscle cells and
endothelium was tested using phenylephrine (PE; 10
-6
mol/L). After wash out and another 30 min of stabilization,
endothelial function was measured as endothelium-depen-
dent relaxation to cumulative concentration of acetylcho-
line (ACh; 3 9 10
-8 - 3 9 10
-4 mol/L) in the vessels
precontracted by PE (10
-6 mol/L). Area under the curve
(AUC) was obtained as measure for endothelial function.
Finally, sodium nitroprusside (10
-3mol/L) was added to
the organ baths to obtain endothelium-independent relax-
ation. In order to examine the role of cyclo-oxygenase
(COX) [44], Ach-induced relaxation was studied in parallel
in separate aortic rings in the presence of either 10
-6 M
indomethacin or 10
-5 nimsulin, to inhibit COX1 and
COX2, or only COX2, respectively.
Aortic sections are processed for analysis of endothelial
nitric oxide synthase (e-NOS) expression using RT-PCR.
For that, total RNA was isolated using TRIzol reagent
(Invitrogen Corporation, Breda, The Netherlands) and
converted to cDNA by QuantiTect Reverse Transcription
(Qiagen, Venlo, The Netherlands). Gene expression was
measured with Absolute QPCR SYBR Green ROX Mix
(Abgene, Epsom, UK) in the presence of 7.5 ng cDNA and
200 nM forward and reverse primers. qRT-PCR was con-
ducted on the Biorad CFX384 (Biorad, Veenendaal, The
Netherlands). Initial denaturation and activation of the
DNA polymerase at 95C for 3 min was followed by 35
cycles with denaturation for 15 s at 95C and annealing
and elongation for 30 s at 60C, followed by a melt curve.
Gene expression levels were corrected for ribosomal pro-
tein large (Rplp0). Primers used were endothelial NO
synthase (eNOS) forward TCCTAACTTGCCTTG-
CATCC, eNOS reverse GGCAGCCAAACACCAAAGTC,
Rplp0 forward CCTCATACCAGCGACGATTC, Rplp0
reverse ATGTGGAGGAGTCTCACTTC.
Statistical analysis
Data are presented as mean ± standard error of the mean
(SEM). Data of rats with infarct\20% of the left ventricle
were excluded from analysis, as these small infarcts are
hemodynamically fully compensated [37]. Analyses were
performed using SPSS version 16. Parameters were com-
pared using 2-way analysis of variances (ANOVA); effects
of cardiac dysfunction as well as renal dysfunction were
analyzed ﬁrst separately, followed by analysis of
interaction. This is presented in the ﬁgures using different
symbols. In case data were not normally distributed, a non-
parametric Kruskal–Wallis test followed by a Mann–
Whitney U test with correction for multiple comparisons
was used. Differences were considered signiﬁcant at the
level of 0.05.
Echocardiography could be obtained in only 3–5 rats
per group, and hence results should be regarded as indi-
cation, rather than as group evaluation with statistical
analysis.
Results
Control rats
Twelve weeks old rats from both strains (MWF = RD;
Wistar = control) were sacriﬁced to obtain baseline val-
ues, and general characteristics are presented in Table 1.
Food and water intake did not differ between RD rats and
controls, nor did urine production. RD rats had a lower
body weight than age-matched control. Lung weight and
Table 1 Characterization of control (Wistar) and RD (MWF) rats at
12 weeks of age
Group Control RD
N 55
BW (g) 386 ± 7 249 ± 14
a
Food intake (g/24 h) 15 ± 41 9 ± 1
Water intake (ml/24 h) 24 ± 32 6 ± 2
Urine production (g/24 h) 15 ± 21 1 ± 1
HW/BW (mg/g) 3.2 ± 0.2 4.5 ± 0.5
a
Lung/BW (mg/g) 3.3 ± 0.0 4.8 ± 0.2
a
RKW/BW (mg/g) 3.7 ± 0.1 3.7 ± 0.1
UPE (mg/24 h) 28 ± 57 6 ± 19
a
FGS (AU) 0.4 ± 0.4 1.6 ± 0.4
a
Plasma creat (mg/L) 31 ± 12 5 ± 4
MAP (mmHg) 89 ± 4 102 ± 3
a
LVSP (mmHg) 117 ± 5 131 ± 3
a
LVEDP (mmHg) 5.3 ± 2.4 6.2 ± 1.9
HR (beats/min) 359 ± 18 364 ± 14
CVP (mmHg) 1.2 ± 1.9 2.1 ± 1.7
RBF/KW (ml/min/g) 6.0 ± 1.6 2.6 ± 0.6
a
Hct (%) 47.6 ± 0.4 44.2 ± 0.3
a
HW heart weight, BW body weight, RKW right kidney weight, UPE
urinary protein excretion, FGS focal glomerulosclerosis, Creat cre-
atinine levels, MAP mean arterial pressure, LVSP left ventricular
systolic pressure, LVEDP left ventricular enddiastolic pressure, HR
heart rate, CVP central venous pressure, RBF renal blood ﬂow, Hct
hematocrit
a Signiﬁcant difference between control and RD
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increased in RD. At 12 weeks of age, renal dysfunction
was conﬁrmed by increased urinary protein excretion
(UPE) and focal glomerulosclerosis (FGS) in RD, but no
increase in plasma creatinine levels was observed. RD rats
had slightly higher blood pressures, reﬂected in a 29%
increase in left ventricular myocyte cross-sectional area
(NS), with normal heart rate and normal left (LVEDP) and
right (CVP) cardiac ﬁlling pressures. Renal blood ﬂow,
however, was strongly reduced in RD due to elevated renal
vascular resistance (47 ± 12 vs. 17 ± 4 mmHg/ml/min, in
RD and control, respectively). Hematocrit was signiﬁcantly
lower in RD rats.
Apart from a slightly increased myocyte size, histolog-
ical analysis showed no signs of adverse left ventricular
remodeling in RD; myocyte cross-sectional area 535 ± 71
versus 414 ± 48 lm
2; interstitial ﬁbrosis: 5.0 ± 0.9 versus
5.9 ± 0.5%; capillary density: 2,891 ± 337 versus
2,156 ± 141 #/mm
2; number of capillaries per cardiomy-
ocyte 1.92 ± 0.28 versus 1.14 ± 0.19, in RD versus con-
trol, respectively.
Myocardial infarction
Cardiac dysfunction was induced by experimental myo-
cardial infarction (MI). This procedure resulted in 22%
mortality, which occurred mainly within the ﬁrst 24 h after
surgery. Overall infarct size was not different in both
groups (33 ± 5% in CD and 34 ± 4% in CRD), neither
after exclusion of 3 rats with infarcts\20% (34 ± 5% in
CD and 38 ± 3% in CRD).
Characteristics of experimental groups at 25 weeks are
presented in Table 2. Strain-related characteristics as seen
at 12 weeks (Table 1) remained present in sham groups at
25 weeks. Whereas plasma concentrations of electrolytes
did not differ between groups, concentrations in urine were
signiﬁcantly higher in rats with RD. MI had no effect on
electrolyte concentrations in urine.
Renal effects
Time course of UPE is shown in Fig. 1. As anticipated, RD
rats showed progressive proteinuria with age, which was
absent in controls and CD rats. When renal dysfunction
was combined with cardiac dysfunction in CRD, besides an
initial decrease, proteinuria progressed at the same rate as
in RD. The initial decrease occurred in both MI groups, CD
and CRD, at the same percentage. In RD, FGS increased
with age from 1.6 ± 0.4 AU at 12 weeks to 22.4 ± 2.1 AU
Table 2 General characteristics
of the experimental groups at
25 weeks of age
BW body weight, Hct
hematocrit, HW heart weight,
RKW right kidney weight, FGS
focal glomerulosclerosis, MI
myocardial infarction, CD
cardiac disease, RD renal
disease, CRD cardiorenal
disease
a Signiﬁcant effects of cardiac
dysfunction
b Signiﬁcant effect of renal
dysfunction
Group Control CD RD CRD
N 10 6 9 10
BW (g) 482 ± 11 466 ± 14 340 ± 9
b 342 ± 8
b
Food intake (g/24 h) 11 ± 21 3 ± 31 3 ± 11 1 ± 1
Water intake (ml/24 h) 21 ± 12 6 ± 52 2 ± 12 2 ± 1
Urine production (g/24 h) 15 ± 21 8 ± 31 3 ± 11 4 ± 1
Hct (%) 47.8 ± 0.6 48.7 ± 1.0 45.0 ± 0.8
b 45.7 ± 0.7
b
Plasma [Na] (mmol/L) 137 ± 1 138 ± 1 137 ± 0 136 ± 1
Plasma [K] (mmol/L) 4.4 ± 0.2 4.7 ± 0.2 4.5 ± 0.1 4.7 ± 0.1
Plasma [Cl] (mmol/L) 102 ± 1 103 ± 1 105 ± 1 104 ± 0
Urine [Na] (mmol/L) 92 ± 17 123 ± 36 147 ± 11
b 159 ± 22
b
Urine [K] (mmol/L) 115 ± 15 125 ± 23 153 ± 9
b 152 ± 21
b
Urine [Cl] (mmol/L) 101 ± 20 136 ± 40 176 ± 13
b 184 ± 25
RKW/BW (mg/g) 3.7 ± 0.1 3.3 ± 0.1
a 3.3 ± 0.1
b 3.1 ± 0.1
b
FGS (AU) 2.4 ± 0.6 3.6 ± 1.2 22.4 ± 2.1
b 12.1 ± 1.4
b
Fig. 1 Time course of urinary protein excretion in the experimental
groups. Control (n = 10), CD cardiac disease (n = 6), RD renal
disease (n = 6), CRD cardiorenal disease (n = 10).
?Signiﬁcant
effect of renal dysfunction
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proteinuria, with no additional increase due to concomitant
cardiac dysfunction. In fact, there was a highly signiﬁcant,
positive correlation between UPE and FGS (r
2 = 0.64,
p\0.001). RBF was signiﬁcantly lower in RD and was
not affected by MI in either strain (Table 3). RVR was
signiﬁcantly higher in RD rats than in controls
(52.8 ± 13.1 and 13.2 ± 1.9 mmHg/ml/min, respectively),
but not signiﬁcantly affected by MI (CRD 39.5 ± 6.9
mmHg/ml/min; CD 13.5 ± 1.3 mmHg/ml/min). This
hemodynamic renal parameter RVR was signiﬁcantly,
negatively correlated with both structural (FGS; r
2 = 0.473,
p\0.001) and functional (UPE; r
2 = 0.328, p = 0.002)
renal parameters.
Creatinine clearance was similar in all groups (control
8.2 ± 0.9; CD 7.3 ± 0.2; RD 10.0 ± 1.3 and CRD
9.1 ± 1.1 ml/min/kg) and decreased approximately 25%
with aging irrespective of absence/presence of MI. No
signiﬁcant correlations of creatinine clearance with other
renal parameters were found.
Cardiac effects
Effects on cardiac function
Time course of cardiac dysfunction is presented in Fig. 2a
and b. The EF (Fig. 2a) was 85% in sham rats and
remained stable over time. At 3 weeks, EF was severely
Table 3 Systemic and cardiac hemodynamics measured at 25 weeks of age
Group Control CD RD CRD
N 10 6 9 10
HR (b/min) 331 ± 14 336 ± 35 360 ± 28 416 ± 38
MAP (mmHg) 94 ± 38 8 ± 4 107 ± 4
b 84 ± 5
a
LVSP (mmHg) 128 ± 4 123 ± 8 134 ± 3 108 ± 2
ac
?dP/dt (mmHg/s) 9,091 ± 299 7,463 ± 375
a 8,993 ± 318 8,452 ± 455
a
-dP/dt (mmHg/s) 7,463 ± 375 6,009 ± 432
a 6,199 ± 513 4,377 ± 299
ac
RBF/KW (ml/min.g) 7.1 ± 0.8 6.7 ± 0.4 2.8 ± 0.7
b 2.7 ± 0.5
b
CD cardiac disease, RD renal disease, CRD cardiorenal disease, HR heart rate, MAP mean arterial pressure, LVSP left ventricular systolic
pressure, ±dP/dt positive/negative ﬁrst derivative of pressure signal, RBF/KW renal blood ﬂow/kidney weight
a Signiﬁcant effects of cardiac dysfunction
b Signiﬁcant effect of renal dysfunction
c Signiﬁcant effect of combined cardiorenal dysfunction
Fig. 2 Cardiac function
parameters obtained by
echocardiography. E/e0 early
ﬁlling velocity (E) to mitral
valve septal annular velocity
(e0) ratio. Control (n = 5), CD
cardiac disease (n = 3), RD
renal disease (n = 5), CRD
cardiorenal disease (n = 4)
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level for the rest of the study. CO (Fig. 2b) showed similar
and stable values in sham rats of both strains. Three weeks
after MI, CO was strongly depressed and remained low in
CRD, but was partly restored in CD.
Cardiac function and hemodynamics parameters mea-
sured 12 weeks after surgery, are presented in Table 3.
Heart rate was similar in control rats, rats with CD and
rats with RD, but higher (p = 0.06) in rats with CRD. RD
rats had higher MAP than control, which was signiﬁcantly
reduced after MI. MI reduced left ventricular systolic
pressure by 4% in CD, but by 20% in CRD. Whereas MI-
induced reduction of left ventricular systolic function
(?dP/dt), was not exaggerated in CRD compared to CD,
diastolic dysfunction, presented as a reduction of relaxa-
tion velocity (-dP/dt) as well as increase in tissue
Doppler parameter (E/e’), was signiﬁcantly more pro-
nounced in CRD (Fig. 2c). Moreover, heart weight–body
weight ratio, as well as lung weight–body weight ratio
was signiﬁcantly higher in the CRD rats (Fig. 3).
Parameters of congestion, upstream from the injured left
ventricle were analyzed and presented in Fig. 3. LVEDP
was increased by 80% in CD, but almost by 200% in
CRD, indicating elevated left ventricular preload. Simi-
larly, left atrial weight increased 3 times more in CRD
than in CD. Twice as high right atrial weight only in
CRD rats suggests that congestion was not restricted to
the damaged left side of the heart. In addition, central
venous pressure appeared highest in the CRD rats,
although no signiﬁcant differences could be obtained
between the experimental groups.
Effects on myoﬁlament function
Myoﬁlament function of isolated skinned ﬁbers from the
viable left ventricular free wall is presented in Fig. 4.
Whereas active force was similar in all groups, passive
force increased after MI. This increase was found statisti-
cally signiﬁcant in CRD, but not in CD.
Effects on cardiac structure
Histological analysis of left ventricle of 25 weeks old sham
rats revealed similar effects to those of 12 weeks old rats
(Fig. 5). MI signiﬁcantly reduced capillary density to the
same extent in CD and CRD. Similarly, interstitial collagen
and myocyte size were increased due to MI, but without
differences between CRD and CD. Furthermore, no dif-
ferences between the groups are found for number of
capillaries per myocyte (range 1.8–2.3).
Myocyte size in the right ventricle was signiﬁcantly and
exponentially (p\0.001) increased in rats with CRD
(Fig. 5), and was signiﬁcantly and positively correlated
with congestion parameters, such as LVEDP, atrial weight
and lung weight. Hence, right ventricular myocyte size
may better explain the increased heart weight body weight
ratio (r
2 = 0.418; p\0.001) in rats with CRD than left
ventricular myocyte size (r
2 = 0.002; p = 0.797).
Fig. 3 Parameters of congestive heart failure. Control (n = 10), CD
cardiac disease (n = 6), RD renal disease (n = 9), CRD cardiorenal
disease (n = 10). LVEDP left ventricular enddiastolic pressure, CVP
central venous pressure.
?Signiﬁcant effects of renal dysfunction;
#
Signiﬁcant effect of combined cardiorenal dysfunction
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Effect on blood
Before MI, plasma renin activity (PRA) was signiﬁcantly
lower in RD compared to control rats; 4.4 ± 0.5 versus
8.0 ± 0.8 ngAngI/ml/h. MI induced a signiﬁcant increase
in PRA only in CRD rats (altered PRA from before- to
7 weeks post-MI: CRD ?6.2 ± 1.6; CD -2.1 ± 2.5; RD
-1.2 ± 1.2; control -2.5 ± 1.0 ngAng I/ml/h). This
increased PRA was signiﬁcantly correlated with LVEDP
(r
2 = 0.461, p\0.001), lung weight (r
2 = 0.515,
Fig. 4 Active and passive force
development in isolated
myoﬁbrils. Control (n = 5), CD
cardiac disease (n = 5), RD
renal disease (n = 5), CRD
cardiorenal disease (n = 5).
*Signiﬁcant effect of cardiac
dysfunction
Fig. 5 Left and right
ventricular remodeling
presented as interstitial
collagen, capillary density and
myocyte hypertrophy. Control
(n = 10), CD cardiac disease
(n = 5), RD renal disease
(n = 9), CRD cardiorenal
disease (n = 10). *Signiﬁcant
effects of cardiac dysfunction;
#Signiﬁcant effect of combined
cardiorenal dysfunction
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123p\0.001) and right ventricular myocyte size (r
2 = 0.175,
p = 0.042), but not with renal parameters, such as pro-
teinuria, creatinine and renal blood ﬂow.
Before MI, there was no difference in BNP levels
between groups. MI induced highest increase of BNP in
CRD rats (altered BNP from before to 7 weeks post-MI:
CRD 1.1 ± 0.2; RD 0.3 ± 0.4; CD 0.5 ± 0.2; control
0.6 ± 0.2 ng/ml). BNP values 7 weeks post-MI were
positively correlated with lung (r
2 = 0.184, p = 0.014)
and atrial weights (r
2 = 0.215, p = 0.008 and r
2 = 0.138,
p = 0.040 for left- and right atrium, respectively), but not
with renal parameters.
MI in CD did not affect hematocrit, nor number of red
blood cells (Table 4). However, number of white blood
cells was signiﬁcantly reduced after MI. In RD, lower
hematocrit levels shown at 12 weeks of age, were also
observed at 25 weeks, and matched with lower numbers of
red blood cells (Table 4). Number of white blood cells was
pronouncedly reduced in RD. In CRD, MI did not affect
hematocrit, number of red blood cells, or number of white
blood cells. Platelet numbers were similar in all groups.
Vascular effects
There were no differences between groups with regard to
aortic media/lumen ratio at 12 weeks after MI (control
0.23 ± 0.03; CD 0.23 ± 0.04; RD 0.25 ± 0.2: CRD
0.28 ± 0.02). There was a slight increase in total periph-
eral resistance in CD rats from 0.71 ± 0.07 to
0.95 ± 0.10 mmHg min/ml, and in CRD from 0.81 ± 0.07
to 1.04 ± 0.18 mmHg min/ml. A signiﬁcant correlation was
found between TPR and left ventricular congestion param-
eters, LVEDP and left atrial weight (r
2 = 0.328, p = 0.026;
r
2 = 0.355, p = 0.016, resp.), but not with pulmonary and
right ventricular congestion parameters, nor with renal
parameters.
In aortic rings, endothelium-independent relaxation,
obtained by response to sodium nitroprusside, was reduced
by 23% (NS) in CD and RD and by 53% in CRD rats
(p\0.05). Moreover, endothelium-independent relaxation
was signiﬁcantly correlated with congestion parameters
LVEDP, left atrial weight and lung weight, but not with
any of the renal parameters.
Endothelium-dependent relaxation, obtained by the
response to acetylcholine, is presented in Fig. 6a. RD
caused a signiﬁcant reduction in endothelium-dependent
relaxation (AUC control 99.0 ± 14.8 AU; RD: 54.6 ± 11.9
AU), which was maintained after correction for endothe-
lium-independent relaxation. CD did not signiﬁcantly impair
endothelium-dependent relaxation (AUC 93.0 ± 37.8 AU).
Although not statistically signiﬁcant, an additional effect
might be seen in the vessels from CRD rats (AUC 32.8 ±
9.4 AU). Interestingly, endothelium-dependent relaxation
was signiﬁcantly correlated with both renal dysfunction
parameters as well as left ventricular overload parameters
(Fig. 7), but not with systemic hemodynamic parameters,
such as TPR, MAP and CVP.
Endothelial NO-synthase expression was slightly
increased in aortas of rats with renal dysfunction, but
without additional effects of MI (eNOS/Rplp0 in control
0.82 ± 0.15; CD 0.75 ± 0.27; RD 1.11 ± 0.20; CRD
1.18 ± 0.17).
Effects of COX inhibition on Ach-induced relaxation is
presented in Fig. 6b. In control as well as RD, COX2
inhibition by nimsulide enhanced the Ach-induced relaxa-
tion, whereas COX1 and COX2 inhibition by indomethacin
had no effect, indicating a COX1 mediated vasodilation
compensated by COX2 mediated vasoconstriction. MI had
similar effects in CD as well as CRD; no effect of
nimsulide, but increased vasorelaxation on indomethacin.
Discussion
Even mild renal dysfunction substantially increases the risk
of cardiovascular morbidity or mortality, and many patients
with heart failure suffer from concomitant renal dysfunc-
tion, supporting a strong interaction between heart and
kidneys. Primary chronic kidney disease is associated with
extremely high cardiovascular risk [36].
Table 4 Effects on hematocrit (Hct), number of red- (RBC) and white (WBC) blood cells, and platelets
Group Control CD RD CRD
N 10 5 9 9
Hct (%) 47.8 ± 0.6 48.7 ± 1.0 45.0 ± 0.8
b 45.7 ± 0.7
b
RBC (#.10
12/l) 9.4 ± 0.1 9.4 ± 0.1 7.9 ± 0.2
b 7.8 ± 0.1
b
WBC (#.10
12/l) 10.7 ± 0.8 8.7 ± 0.6
a 2.2 ± 0.2
b 2.3 ± 0.1
b
Platelets (#.10
12/l) 739 ± 68 852 ± 49 887 ± 44 832 ± 40
CD cardiac disease, RD renal disease, CRD cardiorenal disease, # number
a Signiﬁcant effects of cardiac dysfunction
b Signiﬁcant effect of renal dysfunction
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123The interaction between heart and kidneys in this rela-
tively high-risk group of patients was studied in an animal
model mimicking the clinical condition; rats that sponta-
neously develop progressive renal dysfunction, subjected
to experimentally induced heart failure. The main ﬁndings
were: (1) cardiac, but not renal dysfunction was exagger-
ated in combined cardiorenal dysfunction; (2) cardiac
dysfunction was characterized by systolic and diastolic
Fig. 6 Parameters of
endothelial function.
a Concentration-dependent
relaxation to acetylcholine in
phenyleprine-precontracted
aortic rings. b Effect of COX
inhibition on maximal Ach-
induced relaxation. Control
(n = 6), CD cardiac disease
(n = 4), RD renal disease
(n = 6), CRD cardiorenal
disease (n = 5). CTRL control
conditions, INDO indomethacin,
NIM nimesulide;
?Signiﬁcant
effect of renal dysfunction
Fig. 7 Statistically signiﬁcant
correlations between endothelial
function and renal as well as
cardiac parameters
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123dysfunction with cardiopulmonary congestion and right
ventricle hypertrophy; (3) adverse left ventricular remod-
eling and myoﬁlament dysfunction could not explain the
deteriorated cardiac function in cardiorenal disease; (4)
vascular endothelial dysfunction may provide a link
between renal and cardiac dysfunction.
Rat model for cardiorenal disease
As anticipated from literature [35], renal dysfunction in
12 weeks old RD rats was conﬁrmed by functional, struc-
tural and hemodynamic changes, represented by increased
UPE and FGS and reduced renal blood ﬂow, respectively.
Furthermore, hematocrit levels were reduced, which is in
agreement with previous ﬁndings in rats [1], as well as in
patients with chronic renal disease [23, 46], and notiﬁed as
a ‘‘novel’’ risk factor in cardiorenal disease [47]. RD
coincided with mildly increased MAP and normal CVP
[24].
Combining this model with experimental myocardial
infarction, a well-established model of cardiac dysfunction
[37, 38], may therefore provide a suitable animal model to
study chronic renal dysfunction as predisposition for high
cardiovascular risk.
Renal dysfunction in cardiorenal disease
There was no effect of cardiac dysfunction on progres-
sion of renal dysfunction as evidenced by functional
(UPE), hemodynamic (RVR) and structural (FGS)
parameters. Apart from the initial decrease, the pro-
gression of UPE in CRD was similar to that in RD.
Since this initial decrease occurred to the same extent in
CD and CRD rats, it might be attributed to reduction in
MAP shortly after MI. The absence of progressive pro-
teinuria is in contrast to results reported in rats after
unilateral nephrectomy and MI [48], but in accordance
with the commonly used cardiorenal model of rats with
subtotal nephrectomy and MI [55, 56]. Renal dysfunction
in RD and CRD resulted in increased FGS in comparison
to control and CD; however, it was lower in CRD than
in CD. When taking the strong correlation between UPE
and FGS, it seems that this difference may have also
occurred in the early post-MI phase. RVR was severely
increased in RD compared to control, but without addi-
tional increase in CRD. All these functional, hemody-
namic and structural parameters of renal dysfunction
were signiﬁcantly inter-correlated, supporting mutual
interaction of renal parameters and substantiating the
observation of absence of progressive renal dysfunction
due to concomitant cardiac dysfunction.
In contrast, creatinine clearance, as an estimate of glo-
merular ﬁltration rate, was reduced over time, but not
different between experimental groups. This would support
recent suggestions that proteinuria and reduced glomerular
ﬁltration rate may represent different types of renal dys-
function, rather than being a measure of increased severity
[5]. Finally, no correlations were found between renal
parameters and cardiac parameters, indicating absence of a
direct relationship in the present study.
Although not accelerated by concomitant cardiac dys-
function, renal function still was declining over time in
CRD. It is generally acknowledged that worsening of renal
function can lead to worsening of cardiac function and
outcome in patients, as reviewed by Damman and co-
workers [6]. However, to our knowledge there are no
clinical studies available investigating the opposite rela-
tion: comparing worsening of renal function in patients
with or without concomitant cardiac dysfunction.
Cardiac dysfunction in cardiorenal disease
Calculated CO provided a ﬁrst indication of more severe
cardiac dysfunction in rats with primary renal dysfunction.
Accelerated cardiac dysfunction in CRD, as indicated by
lower CO, was substantiated by exponential increases in
left ventricular overload parameters, congestion and fail-
ure. Comparing our results to available literature reveals
that accelerated cardiac dysfunction was not observed in
unilateral nephrectomy ? MI [48] or in 5/6 nephrec-
tomy ? MI [56], whereas rats with temporal L-NNA
infusion, in addition to 5/6 nephrectomy, did show signs of
more severe cardiac dysfunction [1]. However, one recent
study is showing aggravation of cardiac remodeling with
concomitant renal dysfunction [10]. Unfortunately, this
study did not include rats with only 5/6 nephrectomy or
sham MI rats. Moreover, control rats did not show cardiac
dysfunction after MI as measured by EF or LVEDD, and
changes in cardiac function and remodeling could well be
attributed to the larger infarct sizes in the cardiorenal group
[10].
Since the congestion in systolic heart failure is related to
renal dysfunction and increased mortality [7], many studies
focused on systolic dysfunction. However, in a substantial
proportion of cardiorenal disease patients, cardiac dys-
function is characterized by diastolic rather than systolic
dysfunction; heart failure with preserved ejection fraction
[29, 32]. Data from the present study indicate that rats with
CRD may display diastolic heart failure indicated by
stronger reduction in cardiac output at similar ejection
fraction, increased E/e’ ratio and signs of congestion. This
was accompanied by right ventricular overload, indicative
for pulmonary hypertension, as commonly observed in
cardiorenal diseased patients [26]. In a recent study, it was
argued that diastolic dysfunction only develops into con-
gestive diastolic heart failure because of underlying renal
Basic Res Cardiol (2012) 107:242 Page 11 of 15
123insufﬁciency [51], which underscores the relevance of our
model.
Underlying mechanisms
Adverse cardiac remodeling
In 12 weeks old MWF, a cardiac phenotype was indicated
fromhigherheartweight–bodyweightratiosassociatedwith
increased left ventricular systolic pressure at normal end-
diastolic pressure. Three months of CRD resulted in pro-
nouncedly increased cardiac weight, suggesting adverse
cardiac remodeling [43]. However, besides a minor, and
possibly blood pressure-related left ventricular myocyte
hypertrophy,adverseremodelingoftheleftventriclewasnot
observed either at 12 or at 25 weeks. Thus, adverse left
ventricular remodeling neither was a predisposition to
develop accelerated cardiac dysfunction in CRD, nor could
be associated with the exaggerated cardiac dysfunction in
CRD, once established. This is in accordance with results in
ratswith5/6nephrectomy ? MI[34,56],butincontrasttoa
recent study of Dikow et al. [10]. In this latter study, how-
ever,effectsonremodelingwereonlyobservedintheborder
zoneofthescarandnotintheremoteareas,andhencewould
match with our results obtained in remote areas.
In the present study, increased pulmonary weight sug-
gested pulmonary congestion and right ventricular over-
load. This was evidenced by a signiﬁcant increase in right
ventricular myocyte size, indicating right ventricular con-
centric hypertrophy, and could be associated with the
activated renin angiotensin system in CRD. A higher cor-
relation between total ventricular weight and right-, com-
pared to left ventricular myocyte size, supports an
important contribution of the right ventricle to increased
heart weight in CRD. Moreover, right ventricle overload
might have also contributed to the dysfunction of LV [4].
Myoﬁlament function
Cardiac diastolic dysfunction could be caused by various
mechanisms [11], including altered function of contractile
proteinswithinthecardiomyocyte.Whereasactiveforcewas
similarinallgroups,passiveforcewassigniﬁcantlyincreased
inCRD.Correlationwithimpairedleftventricularrelaxation
indicated intrinsic diastolic dysfunction rather than ﬁbrosis-
related stiffness of the left ventricle. High cardiomyocyte
stiffness has been reported in diastolic dysfunction patients
and correlated signiﬁcantly with LVEDP [2].
Anemia
Irrespective of concomitant cardiac dysfunction, MWF
showed anemia, indicated by lower hematocrit as well as
number of red blood cells. Since white blood cell number is
even more pronouncedly decreased, anemia may result
from general bone marrow dysfunction rather than from
hemodilution or erythrocyte-speciﬁc mechanisms, such as
erythropoietin-resistance [23]. This is supported by results
of a pilot study of culturing bone marrow-derived endo-
thelium progenitor cells [33], showing less than 10%
yield in MWF compared to Wistar. All aspects, including
anemia [23, 25], erythropoietin-resistance [39], reduced
number/and or function of endothelium progenitor cells
[3, 16, 40], general bone marrow dysfunction [21, 22], are
commonly described in renal dysfunction. However, as no
additional effects were observed in CRD rats compared to
CD and RD rats, this does not provide an explanation for
the accelerated cardiac dysfunction in primary renal
dysfunction.
Vascular function
Endothelial dependent relaxation measured in aortic rings
served as a biomarker for endothelial dysfunction in more
distant vascular beds. MI has been associated with reduced
endothelium-dependent relaxation in aortic rings [13, 53].
Moreover, impaired endothelium-dependent relaxation in
aortic rings in MWF [44] could be associated with endo-
thelial dysfunction in coronary, but not in mesenteric
arteries [15]. There is growing evidence of the role of
endothelium in regulation of cardiac diastolic function
[54]. It is believed that low availability of NO produced by
endothelial NO synthase leads to decrease in diastolic
function, cardiac hypertrophy and ﬁbrosis, whereas
enhancement of this enzyme attenuates these changes.
Endothelium derived NO has been shown to have positive
effects not only on diastolic, but also on systolic function
[18]. Moreover, the endothelial dysfunction might limit the
cardioprotective effect of erythropoietin [42]. Therefore,
exaggerated endothelial dysfunction in CRD might have
contributed to further impairment of cardiac dysfunction in
these rats. However, as eNOS expression in the present
study was similar in RD and CRD and even slightly higher
compared to control and CD, impaired eNOS would not
explain the endothelial dysfunction in CRD. Similarly, MI-
induced altered COX-activity was comparable in CD and
CRD and hence may not have contributed to endothelial
dysfunction in CRD. Unfortunately, to our knowledge no
data are available about endothelial function in renal
arteries in MWF. Interestingly, aortic endothelial function
was the only parameter that signiﬁcantly correlated with
renal as well as cardiac parameters, suggesting a mediating
role for the vasculature. This suggested role may be sup-
ported by the ﬁnding that endothelial function predicts
individual susceptibility to renal damage in 5/6 nephrec-
tomy [14, 30, 31].
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Although the present study may throw new light on the
interaction between heart and kidneys in cardiorenal dis-
ease, it may have some limitations as well: the MWF rat
strain used in this study is an inbred model based on pro-
teinuria, which could have caused other unknown geno-
typical/phenotypical changes as well; we cannot fully
exclude primary pulmonary disease in this strain. More-
over, as most inbred Wistar-origin models, MWF rats had
substantially lower body weights at the same age than out-
bred Wistar. Although a clear explanation is to our
knowledge not known, it may trouble either/not correcting
for body weight. Furthermore, although proteinuria, focal
glomerulosclerosis, mild hypertension and reduced renal
blood ﬂow are well known in the MWF’s, reduced GFR as
often seen in cardiorenal patients was not present in the
MWF. Finally, the ﬁrst indication for exaggerated cardiac
dysfunction came from echocardiographical measurements
only performed in a subgroup of rats, which clearly ham-
pers proper statistical analysis.
Conclusion
In conclusion, experimental MI did not exaggerate renal
dysfunction in the proteinuric MWF rat. However, cardiac
dysfunction was exaggerated by this primary renal dys-
function. The accelerated cardiac dysfunction could be
characterized by elevated left ventricular preload, as well
as pulmonary congestion, right ventricular overload and
right ventricular hypertrophy. This animal model may
provide an important step to understand the complex
clinical condition of cardiorenal disease. Finally the study
provides evidence that vascular endothelial dysfunction
may play a mediating role in this cardiorenal interaction.
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